1. Introduction
===============

As known, the Chinese nation, with a history of more than 5000 years of civilization, largely relies on Traditional Chinese Medicine (TCM). TCM still plays a huge role in health care, disease prevention and treatment in China today. This is the reason why TCM has been deeply rooted in China and other Chinese cultural circles around the world for thousands of years. Traditional medicine, especially TCM, is not only an important and indispensable "alternative medicine" or "complementary medicine", but has also been entrusted with hopes for disease prevention and treatment in the future.

Traditional Chinese medicine prescriptions (TCMPs), or TCM formulae, which are applied according to certain compatibility rules, are the main and important clinical applications of TCM. However, TCMPs are facing difficulties because their effective constituents are unclear and sometimes inexplicable, which seriously restricts their development in the international market \[[@B1-molecules-20-01594]\]. The chemical constituents of TCMPs are the key object of the study of TCM \[[@B2-molecules-20-01594]\]. TCM is commonly considered to operate due to the synergistic effects of all the major and minor components in the medicines. Hence sensitive and comprehensive analytical techniques are needed to acquire a better understanding of the substance basis of TCM and to enhance the product quality control \[[@B3-molecules-20-01594]\].

PSORI-CM01 was a novel formulated Chinese medicine used for psoriasis therapy \[[@B4-molecules-20-01594]\]. It was optimized on the basis of a Chinese medicine formula Yin-Xie Ling, which was originated by Guo-Wei Xuan, the State Medical Master of China \[[@B5-molecules-20-01594],[@B6-molecules-20-01594]\]. PSORI-CM01 was composed of seven herbs including *Rhizoma Curcumae* (E Zhu), *Radix Paeoniae Rubra* (Chi Shao), *Sarcandra glabra* (Zhong-Jie Feng), *Radix Arnebiae* (Zi Cao), *Rhizoma Smilacis Glabrae* (Tu-Fu Ling), *Fructus Mume* (Wu Mei), and *Radix Glycyrrhizae* (Gan Cao). Guo-Wei Xuan believed that one of the main causes of psoriasis is blood stasis. In this TCM formula PSORI-CM01, *Curcumae* bearing blood-activating and stasis-dissolving efficacy acts as the monarch drug, *Paeoniae Rubra*, *Sarcandra glabra* and *Arnebiae*, as the minister drugs, that together help *Curcumae* in activating blood and removing blood stasis. *Smilacis Glabrae* and *Mume* produce the effect of reducing the itch and together act as assistant drugs. *Licorice*, as a guide drug can mediate the other drugs' properties. When combined, the seven drugs have great therapeutic effects. Although the chemical constituents of the individual herbs have previously been well studied \[[@B7-molecules-20-01594],[@B8-molecules-20-01594],[@B9-molecules-20-01594],[@B10-molecules-20-01594],[@B11-molecules-20-01594],[@B12-molecules-20-01594],[@B13-molecules-20-01594],[@B14-molecules-20-01594],[@B15-molecules-20-01594]\], little is known about the integrated chemical composition of PSORI-CM01. Unlike chemical drugs, botanical products contain a complex mixture of compounds. The contents of these compounds may be significantly affected by plant species, geographical sources, harvesting, processing and storage \[[@B16-molecules-20-01594]\]. In addition, three dosage forms of PSORI-CM01 preparations (tablet, granules and decoction) are produced and used clinically in the Guangdong Provincial Hospital of Chinese Medicine. In order to guarantee drug safety and batch-to-batch consistency, quality control is therefore critically important for preparations such as PSORI-CM01. In recent years, the combination of Orbitrap technology with a linear ion trap, known as LTQ Orbitrap mass spectrometer were introduced, which could provide all the traditional MS and MS^n^ scan functions using a linear IT and high mass accuracy measurements (errors within 5 ppm) \[[@B17-molecules-20-01594]\]. Our previous study indicated that this analytical technique has the potential capability of simple, sensitive and reliable detection and identification of complex samples such as TCMs \[[@B9-molecules-20-01594]\].

In the present study, a sensitive LC-ESI-MS^n^ method was established for rapid separating, reliable identifying and quantifying the multiple components in PSORI-CM01 preparations, by using a hybrid LTQ-Orbitrap mass spectrometer coupled with an UHPLC system. The qualitative analysis was carried out in negative ionization mode to acquire accurate mass data in full scan mode and MS/MS in a data dependent product ion spectrum. Further, 14 reference compounds were quantitatively determined in negative ionization mode and eight samples of PSORI-CM01 preparations were analyzed for assessment of quality consistence.

2. Results and Discussion
=========================

2.1. Optimization of Chromatographic Conditions
-----------------------------------------------

To improve the resolution and sensitivity of the analysis but reduce the analytical time, the mobile phase system was optimized. To inhibit ionization of the acidic ingredients in PSORI-CM01, formic acid was added to the mobile phase. Two mobile phase systems, methanol-aqueous solution and acetonitrile-aqueous solution were compared. Both negative and positive modes were examined. Generally, in positive mode, low abundance of \[M+H\]^+^, \[M+NH~4~\]^+^ ions and few product ions were observed, while, in negative ion mode, a series of \[M−H\]^−^ ions and/or adduct ions (\[M+HCOOH−H\]^−^) appeared with sufficient abundance. Thus the negative ion mode was chosen and the \[M−H\]^−^/(\[M+HCOOH−H\]^−^) ions were further subjected to LC-MS^n^ analysis. For the extracted target ions in full scan mode, an accurate mass limit of 5 ppm accurate mass filter limit was used to characterize "real" compounds signals from the background peaks, as well as to increase the signal-to-noise ratio for each analyte.

2.2. Identification of Chemical Constituents in PSORI-CM01 Preparations {#sec2dot2-molecules-20-01594}
-----------------------------------------------------------------------

The reference substances and PSORI-CM01 sample were analyzed by using the optimized LC-ESI-MS^n^ method. The TIC chromatogram of PSORI-CM01 sample in negative ESI mode was shown in [Figure 1](#molecules-20-01594-f001){ref-type="fig"}, and 108 peaks were observed in PSORI-CM01 sample. The MS data showed high precision with all the mass accuracy within 5 ppm. For most of the constituents, \[M−H\]^−^ ions were observed. Due to the use of formic acid in mobile phase, there were adduct ions of \[M+46−H\]^−^ corresponding to \[M+HCOOH−H\]^−^ in negative ion mode. These results provided valuable information for confirming accurate molecular weight and composition of the constituents.

![UHPLC-(-) ESI-MS total ion chromatograms of a mixture of fourteen standards (**A**) and PSORI-CM01 (**B**).](molecules-20-01594-g001){#molecules-20-01594-f001}

One hundred and eight compounds were tentatively identified on the basis of their retention behaviors, accurate molecular weights and MS^n^ fragment data, or by comparison with reference substances or literature data. Corresponding quasimolecular ions and their fragment ions in the MS^n^ spectra were listed in [Table 1](#molecules-20-01594-t001){ref-type="table"}. The identified compounds can be classified into four classes including organic acids, phenolic acids, flavonoids, and terpenoids, which were mainly from *Radix Paeoniae Rubra*, *Rhizoma Smilacis Glabrae*, *Sarcandra glabra,* and *Radix Glycyrrhizae.* Monoterpene glucosides and phenolic acids are the main constituents of *Paeoniae Rubra*, caffeic acid derivatives and flavonoids are abundant in *Sarcandra glabra*, flavonoids and phenolic compounds are mainly from *Rhizoma Smilacis Glabrae*, while flavonoids and triterpene glucoside are from *Radix Glycyrrhizae.* To some extent, the UHPLC-ESI-MS chromatogram reflected the rationale of PSORI-CM01. However, the characteristic constituents (sesquiterpenoids and curcuminoids) from the monarch drug *Rhizoma Curcumae* were not detected.

Among the 108 compounds, 3-*O*-caffeoylquinic acid (**16**), 5-*O*-caffeoylquinic acid (**22**), 4-*O*-caffeoylquinic acid (**24**), 5-*O*-caffeoylskimic acid (**39**), paeoniflorin (**40**), liquiritin (**51**), neoastilbin (**56**), astilbin (**60**), neoisoastilbin (**64**), isoastilbin (**67**), engeletin (**79**), isoengeletin (**82**), liquiritigenin (**87**) and glycyrrhizic acid (**107**) were the main components in PSORI-CM01. Besides, 3-*O*-caffeoylquinic acid (**16**), paeoniflorin (**40**), liquiritin (**51**), astilbin (**60**), engeletin (**79**), liquiritigenin (**87**) and glycyrrhizic acid (**107**) have been reported to have multiple biological activities such as anti-inflammation, immunoregulation and anti-tumor properties \[[@B18-molecules-20-01594],[@B19-molecules-20-01594],[@B20-molecules-20-01594],[@B21-molecules-20-01594],[@B22-molecules-20-01594],[@B23-molecules-20-01594]\], which are related to psoriasis. Thus, these 14 ingredients were selected as markers for quality control.

molecules-20-01594-t001_Table 1

###### 

Identification of the chemical constituents of PSORI-CM01 by UHPLC-ESI-MS^n^ analysis.

  Peak No.   *t*R (min)   SelectedIon   ObservedMass (*m/z*)   CalculatedMass (*m/z*)   Formula           MS/MS PatternsFragmentation   Identifieation                                                                 Source ^a^      Reference
  ---------- ------------ ------------- ---------------------- ------------------------ ----------------- ----------------------------- ------------------------------------------------------------------------------ --------------- ---------------------------------------------------------
  1          0.41         \[M−H\]       191.0559               191.0556                 C~7~H~12~O~6~     191→173, 127, 109             quinic acid                                                                    Sa              \[[@B8-molecules-20-01594]\]
  2          0.51         \[M−H\]       133.0140               133.0137                 C~4~H~6~O~5~      133→115, 87, 71               malic acid                                                                     M               
  3          0.60         \[M−H\]       173.0451               173.0450                 C~7~H~10~O~5~     173→155, 145, 129             shikimic acid                                                                  Sm              \[[@B9-molecules-20-01594]\]
  4          0.88         \[M−H\]       191.0198               191.0192                 C~6~H~8~O~7~      191→173, 155→111              citric acid                                                                    M               
  5          0.98         \[M−H\]       115.0037               115.0031                 C~4~H~4~O~4~      115→97, 71                    fumaric acid                                                                   Sa              \[[@B8-molecules-20-01594]\]
  6          2.16         \[M−H\]       169.0142               169.0137                 C~7~H~6~O~5~      169→125                       gallic acid                                                                    P               \[[@B24-molecules-20-01594],[@B25-molecules-20-01594]\]
  7          2.60         \[M−H\]       331.0663               331.0665                 C~13~H~16~O~10~   331→169                       gallic acid-1-*O*-glucoside                                                    P               
  8          3.28         \[M−H\]       315.0716               315.0716                 C~13~H~16~O~9~    315→297, 247,153              protocatechuic acid-4-*O*-glucoside                                            P, C            
  9          3.64         \[M−H\]       197.0453               197.0450                 C~9~H~10~O~5~     197→153, 123                  syringic acid                                                                  Sa, Sm          \[[@B9-molecules-20-01594]\]
  10         3.69         \[M−H\]       315.0716               315.0716                 C~13~H~16~O~9~    315→169                       gallic acid-1-*O*-rhamnoside                                                   P               
  11         3.78         \[M−H\]       153.0192               153.0188                 C~7~H~6~O~4~      153→109                       protocatechuic acid                                                            Sa,Sm,C         \[[@B8-molecules-20-01594],[@B9-molecules-20-01594]\]
  12         3.82         \[M−H\]       493.1208               493.1193                 C~19~H~26~O~15~   493→313, 169                  gallic acid-1-*O*-glucosyl-(6→1)-glucoside                                     P               
  13         4.02         \[M−H\]       359.0977               359.0978                 C~15~H~20~O~10~   359→197, 179                  syringic acid-4-*O*-glucoside                                                  Sa, Sm          \[[@B9-molecules-20-01594]\]
  14         4.83         \[M−H\]       181.0495               181.0450                 C~9~H~10~O~5~     197→169, 133                  3,5-dimethoxy-4-hydroxy-benzaldehyde                                           Sa              
  15         4.93         \[M−H\]       137.0243               137.0239                 C~7~H~6~O~3~      137→109, 93                   4-hydroxybenzoic acid                                                          C, M, Sm, Sa,   
  16         5.01         \[M−H\]       353.0873               353.0873                 C~16~H~18~O~9~    353→191, 179→135              3-*O*-caffeoylquinic acid                                                      Sa              \[[@B8-molecules-20-01594]\]
  17         5.24         \[M−H\]       165.0556               165.0552                 C~9~H~10~O~3~     165→151, 135                  paeonal                                                                        P               \[[@B24-molecules-20-01594],[@B25-molecules-20-01594]\]
  18         5.31         \[M−H\]       345.1182               345.1186                 C~15~H~22~O~9~    345→183                       (3,5-dimethoxy-4-hydroxyphenyl)methy-*O*-glucoside                             Sa              
  19         5.59         \[M−H\]       183.0296               183.0293                 C~8~H~8~O~5~      183→124                       methyl gallate                                                                 P               
  20         6.20         \[M−H\]       609.1445               609.1456                 C~27~H~30~O~16~   609→445, 301                  rutin                                                                          M               
  21         6.20         \[M−H\]       495.1498               495.1503                 C~23~H~28~O~12~   495→465,333,281               oxypaeoniflorin                                                                P               
  22         6.12         \[M−H\]       353.0872               353.0873                 C~16~H~18~O~9~    353→191, 179, 135             5-*O*-caffeoylquinic acid                                                      Sa              \[[@B8-molecules-20-01594]\]
  23         6.17         \[M−H\]       289.0713               289.0712                 C~15~H~14~O~6~    289→245, 205, 179             (+)-catechin                                                                   P, Sm           \[[@B9-molecules-20-01594]\]
  24         6.18         \[M−H\]       335.0767               335.0767                 C~16~H~16~O~8~    335→289, 179, 135, 111        3-*O*-caffeoylshikimic acid                                                    Sa, Sm          \[[@B9-molecules-20-01594]\]
  25         6.21         \[M−H\]       321.0246               321.0247                 C~14~H~10~O~9~    321→169                       *p*-digallic acid                                                              P               
  26         6.41         \[M−H\]       353.0873               353.0873                 C~16~H~18~O~9~    353→191, 179, 135             4-*O*-caffeoylquinic acid                                                      Sa              \[[@B8-molecules-20-01594]\]
  27         6.43         \[M−H\]       469.1129               469.1135                 C~24~H~22~O~10~   469→423, 371, 315, 289        8-\[β-(3,4-dihydroxyphenyl)-α-carboxyl-3-xoxpropyl\]-substituted catechin      Sm              \[[@B9-molecules-20-01594]\]
  28         6.45         \[M−H\]       179.0345               179.0344                 C~9~H~8~O~4~      179→135, 85                   caffeic acid                                                                   Sa, Sm, A       \[[@B8-molecules-20-01594],[@B9-molecules-20-01594]\]
  29         6.59         \[M+COOH\]    447.1500               447.1503                 C~18~H~26~O~10~   447→401, 349, 317, 191        phenylmethyl-glucoside-(6→1)-apiose                                            M               
  30         6.62         \[M−H\]       221.0452               221.0450                 C~11~H~10~O~5~    221→206                       fraxidin                                                                       Sa              \[[@B8-molecules-20-01594]\]
  31         6.67         \[M−H\]       369.0821               369.0822                 C~16~H~18~O~10~   369→207                       fraxin                                                                         Sa              \[[@B8-molecules-20-01594]\]
  32         6.87         \[M−H\]       435.1289               435.1291                 C~21~H~24~O~10~   435→273                       isoliquiritigenin-7-*O*-glucoside                                              Sa, P           \[[@B8-molecules-20-01594]\]
  33         6.87         \[M−H\]       431.1914               431.1917                 C~20~H~32~O~10~   431→385, 223, 205, 153        drovomifoliol-*O*-glucopyranoside                                              Sa              \[[@B8-molecules-20-01594]\]
  34         6.96         \[M−H\]       433.2070               433.2074                 C~20~H~34~O~10~   433→387, 369 , 225            dihydrovomifoliol-*O*-glucoside                                                Sa              \[[@B8-molecules-20-01594]\]
  35         7.13         \[M−H\]       335.0767               335.0767                 C~16~H~16~O~8~    335→289, 179, 135, 111        4-*O*-caffeoylshikimic acid                                                    Sa, Sm          \[[@B9-molecules-20-01594]\]
  36         7.20         \[M−H\]       289.0712               289.0712                 C~15~H~14~O~6~    289→245, 205, 179             epi-catechin                                                                   P, Sm           \[[@B9-molecules-20-01594]\]
  37         7.23         \[M+COOH\]    525.1604               481.1710                 C~23~H~30~O~11~   525→479, 465, 121             albiflorin                                                                     P               \[[@B24-molecules-20-01594]\]
  38         7.28         \[M−H\]       207.0296               207.0293                 C~10~H~8~O~5~     207→192                       fraxetin                                                                       Sa              \[[@B8-molecules-20-01594]\]
  39         7.38         \[M−H\]       335.0767               335.0767                 C~16~H~16~O~8~    335→289, 179, 135, 111        5-*O*-caffeoylshikimic acid                                                    Sa, Sm          \[[@B9-molecules-20-01594]\]
  40         7.61         \[M+COOH\]    525.1604               481.1710                 C~23~H~30~O~11~   525→479, 327, 283,161         paeoniflorin                                                                   P               \[[@B24-molecules-20-01594],[@B25-molecules-20-01594]\]
  41         7.72         \[M−H\]       471.1863               471.1866                 C~22~H~32~O~11~   471→425, 263                  sarcaglaboside G                                                               Sa              \[[@B8-molecules-20-01594]\]
  42         7.81         \[M−H\]       339.0715               339.0716                 C~15~H~16~O~9~    339→193, 165,137              6,7,8-trihydroxycoumarin-7-rhamnoside                                          Sa, Sm          \[[@B9-molecules-20-01594]\]
  43         7.94         \[M−H\]       629.1514               629.1506                 C~30~H~30~O~15~   629→483, 475, 449, 303, 285   8-\[β-(3,4-dihydroxyphenyl)-α-carboxyl-3-oxopropyl\]-substituted neoastilbin   Sm              \[[@B9-molecules-20-01594]\]
  44         8.05         \[M−H\]       473.2022               473.2023                 C~22~H~34~O~11~   473.202                       sarcaglaboside H                                                               Sa              \[[@B8-molecules-20-01594]\]
  45         8.16         \[M−H\]       629.1514               629.1506                 C~30~H~30~O~15~   629→483, 475, 449, 303, 285   8-\[β-(3,4-dihydroxyphenyl)-α-carboxyl-3-oxopropyl\]-substituted astilbin      Sm              \[[@B9-molecules-20-01594]\]
  46         8.18         \[M−H\]       565.1552               565.1557                 C~26~H~30~O~14~   565→313, 193                  (2*R*/2*S*)-naringenin-6-*C*-β-[d]{.smallcaps}-glucopy ranoside-(6-1)-apiose   Sa              \[[@B8-molecules-20-01594]\]
  47         8.27         \[M−H\]       537.1025               537.1033                 C~27~H~22~O~12~   537→493, 295, 159, 109        lithospermic acid                                                              A               
  48         8.33         \[M−H\]       565.1550               565.1557                 C~26~H~30~O~14~   565→313, 193                  (2*R*/2*S*)-naringenin-6-*C*-glucopyranoside-(6-1)-apiose                      Sa              \[[@B9-molecules-20-01594]\]
  49         8.52         \[M−H\]       629.1514               629.1506                 C~30~H~30~O~15~   629→483, 475, 449, 303, 285   8-\[β-(3,4-dihydroxyphenyl)-α-carboxyl-3-oxopropyl\]-substituted               Sm              \[[@B9-molecules-20-01594]\]
  50         8.57         \[M−H\]       221.0452               221.0450                 C~11~H~10~O~5~    221→206, 191, 163             isofraxidin                                                                    Sa              \[[@B8-molecules-20-01594]\]
  51         8.62         \[M−H\]       417.1186               417.1186                 C~21~H~22~O~9~    417→255                       liquiritin                                                                     G               \[[@B26-molecules-20-01594]\]
  52         8.62         \[M−H\]       549.1607               549.1608                 C~26~H~30~O~13~   549→429, 255                  liquiritin apioside                                                            G               \[[@B26-molecules-20-01594]\]
  53         8.77         \[M−H\]       451.1025               451.1029                 C~24~H~20~O~9~    451→341, 299                  cinchonain Ia                                                                  Sm              
  54         8.80         \[M−H\]       303.0505               303.0505                 C~15~H~12~O~7~    303→285                       taxifolin                                                                      Sm              \[[@B9-molecules-20-01594]\]
  55         8.82         \[M−H\]       300.9986               300.9984                 C~14~H~6~O~8~     301→257                       gallogen                                                                       P               
  56         8.84         \[M−H\]       449.1088               449.1084                 C~21~H~22~O~11~   449→303, 285                  neoastilbin                                                                    Sa, Sm          \[[@B8-molecules-20-01594],[@B9-molecules-20-01594]\]
  57         8.98         \[M−H\]       629.1514               629.1506                 C~30~H~30~O~15~   629→483, 475, 449, 303, 285   8-\[β-(3,4-dihydroxyphenyl)-α-carboxyl-3-oxopropyl\]-substituted isoastilbin   Sm              \[[@B9-molecules-20-01594]\]
  58         8.96         \[M−H\]       631.1656               631.1663                 C~30~H~32~O~15~   631→613, 491, 399, 169        galloyl paeoniflorin                                                           P               
  59         9.02         \[M−H\]       477.0668               477.0669                 C~21~H~18~O~13~   477→301                       quercetin-3-*O*-glucruronide                                                   Sa              \[[@B8-molecules-20-01594]\]
  60         9.02         \[M−H\]       449.1088               449.1084                 C~21~H~22~O~11~   449→303, 285                  astilbin                                                                       Sa, Sm          \[[@B8-molecules-20-01594],[@B9-molecules-20-01594]\]
  61         9.05         \[M−H\]       521.1295               521.1295                 C~24~H~26~O~13~   521→359, 197                  rosmarinic acid-4-*O*-glucoside                                                Sa              
  62         9.38         \[M−H\]       939.1089               939.1104                 C~41~H~32~O~26~   939→769, 617, 393, 317        penta-*O*-galloyl-glucose                                                      P               
  63         9.49         \[M−H\]       515.1184               515.1190                 C~25~H~24~O~12~   515→353                       dicaffeoylquinic acid                                                          Sa              
  64         9.64         \[M−H\]       449.1088               449.1084                 C~21~H~22~O~11~   449→303, 285                  neoisoastilbin                                                                 Sa, Sm          \[[@B8-molecules-20-01594],[@B9-molecules-20-01594]\]
  65         9.68         \[M−H\]       717.1442               717.1456                 C~36~H~30~O~16~   717→519, 475, 321             caffeic acid tetramer                                                          A               
  66         9.78         \[M−H\]       187.0974               187.0970                 C~9~H~16~O~4~     187→142, 125                  nonandioic acid                                                                P, G            
  67         9.84         \[M−H\]       449.1088               449.1084                 C~21~H~22~O~11~   449→303, 285                  isoastilbin                                                                    Sa, Sm          \[[@B8-molecules-20-01594],[@B9-molecules-20-01594]\]
  68         9.87         \[M−H\]       451.1025               451.1029                 C~24~H~20~O~9~    451→341, 299                  cinchonain Ib                                                                  Sm              
  69         9.95         \[M−H\]       717.1442               717.1456                 C~36~H~30~O~16~   717→519, 475, 321             caffeic acid tetramer isomer                                                   A               
  70         9.96         \[M−H\]       597.1605               597.1608                 C~30~H~30~O~13~   597→451, 341, 217             glabraoside C                                                                  Sa              \[[@B8-molecules-20-01594]\]
  71         9.95         \[M−H\]       719.1599               719.1512                 C~36~H~32~O~16~   719→539, 359                  dirosmarinic acid                                                              Sa              
  72         10.08        \[M−H\]       433.1131               433.1135                 C~21~H~22~O~10~   433→343, 313, 271, 179        (2*R*/2*S*)-naringenin-6-*C*-glucopyranoside                                   Sa              \[[@B8-molecules-20-01594]\]
  73         10.17        \[M−H\]       433.1131               433.1135                 C~21~H~22~O~10~   433→343, 313, 271, 179        (2*R*/2*S*)-naringenin-6-*C*-glucopyranoside                                   Sa              \[[@B8-molecules-20-01594]\]
  74         10.36        \[M−H\]       587.2327               587.2340                 C~27~H~40~O~14~   587→451, 341, 217             sarcaglaboside D                                                               Sa              \[[@B8-molecules-20-01594]\]
  75         10.61        \[M−H\]       515.1184               515.1190                 C~25~H~24~O~12~   515→353                       dicaffeoylquinic acid                                                          Sa              
  76         10.64        \[M−H\]       359.0768               359.0767                 C~18~H~16~O~8~    359→197, 161                  rosmarinic acid                                                                Sa, Sm          \[[@B8-molecules-20-01594],[@B9-molecules-20-01594]\]
  77         10.73        \[M−H\]       279.1234               279.1232                 C~15~H~20~O~5~    279→235, 139                  zedoalactone D                                                                 Sa              \[[@B8-molecules-20-01594]\]
  78         10.97        \[M+COOH\]    507.1497               461.1448                 C~23~H~26~O~10~   461→417, 295                  lactiflorin                                                                    P               
  79         11.03        \[M−H\]       433.1132               433.1135                 C~21~H~22~O~10~   433→287, 269                  engeletin                                                                      Sm              \[[@B9-molecules-20-01594]\]
  80         11.41        \[M−H\]       423.1653               423.1655                 C~21~H~28~O~9~    423→261, 243                  chloranoside A                                                                 Sa              \[[@B8-molecules-20-01594]\]
  81         11.80        \[M−H\]       549.1603               549.1608                 C~26~H~30~O~13~   549→417, 255                  isoliquiritin apioside                                                         G               \[[@B26-molecules-20-01594]\]
  82         11.94        \[M−H\]       433.1132               433.1135                 C~21~H~22~O~10~   433→287, 269                  isoengeletin                                                                   Sa, Sm          \[[@B8-molecules-20-01594],[@B9-molecules-20-01594]\]
  83         11.82        \[M−H\]       549.1607               549.1608                 C~26~H~30~O~13~   549→417, 255                  liquiritin apioside                                                            G               \[[@B26-molecules-20-01594]\]
  84         12.40        \[M−H\]       417.1183               417.1186                 C~21~H~22~O~9~    417→255                       isoliquiritin                                                                  G               \[[@B26-molecules-20-01594]\]
  85         12.97        \[M−H\]       599.1756               599.1765                 C~30~H~32~O~13~   599→569                       benzoyloxypaeoniflorin                                                         P               \[[@B24-molecules-20-01594]\]
  86         12.98        \[M−H\]       451.1027               451.1029                 C~24~H~20~O~9~    451→341, 299                  cinchonain Ic                                                                  Sm              \[[@B8-molecules-20-01594]\]
  87         13.06        \[M−H\]       255.0658               255.0657                 C~15~H~12~O~4~    255→135                       liquiritigenin                                                                 G               \[[@B26-molecules-20-01594]\]
  88         13.14        \[M−H\]       451.1025               451.1029                 C~24~H~20~O~9~    451→341, 299                  cinchonain Id                                                                  Sm              \[[@B8-molecules-20-01594]\]
  89         13.33        \[M−H\]       373.0918               373.0923                 C~19~H~18~O~8~    373→211, 161                  methyl rosmarina                                                               Sa, Sm          \[[@B8-molecules-20-01594]\]
  90         13.52        \[M−H\]       823.4102               823.4116                 C~42~H~64~O~16~   823→647, 351                  uralsaponin C                                                                  G               \[[@B27-molecules-20-01594]\]
  91         13.86        \[M−H\]       835.3742               835.3752                 C~42~H~60~O~17~   823→661, 351                  uralsaponin D                                                                  G               \[[@B27-molecules-20-01594]\]
  92         13.52        \[M−H\]       999.4421               999.4433                 C~48~H~72~O~22~   999→837, 645, 351             24-hydroxyl-licorice-saponin A3                                                G               \[[@B27-molecules-20-01594]\]
  93         13.64        \[M−H\]       895.3950               895.3964                 C~44~H~64~O~19~   895→719, 501,351              uralsaponin F                                                                  G               \[[@B27-molecules-20-01594]\]
  94         13.63        \[M−H\]       853.3845               853.3858                 C~42~H~62~O~18~   853→809, 791, 677, 351        22-hydroxyl-licorice-saponin G2                                                G               \[[@B27-molecules-20-01594]\]
  95         13.61        \[M−H\]       983.4470               983.4488                 C~48~H~72~O~21~   983→821, 645, 351             licorice saponin A3                                                            G               \[[@B27-molecules-20-01594]\]
  96         13.68        \[M−H\]       1025.4579              1025.4593                C~50~H~74~O~22~   1025→993, 833, 497            22-acetoxyl-rhaoglycyrrhizin                                                   G               \[[@B27-molecules-20-01594]\]
  97         13.70        \[M−H\]       849.3538               849.3545                 C~42~H~58~O~18~   849→673, 479                  uralsaponin E                                                                  G               \[[@B27-molecules-20-01594]\]
  98         13.76        \[M−H\]       879.3996               879.4014                 C~44~H~64~O~18~   879→861, 643, 351             22-acetoxyl-glycyrrhizin                                                       G               \[[@B27-molecules-20-01594]\]
  99         13.77        \[M−H\]       837.3891               837.3909                 C~42~H~62~O~17~   837→819, 661, 351             24-hydroxyl-glycyrrhizin                                                       G               \[[@B27-molecules-20-01594]\]
  100        13.78        \[M−H\]       271.0607               271.0606                 C~15~H~12~O~5~    271→254, 177                  naringenin                                                                     Sm              \[[@B27-molecules-20-01594]\]
  101        13.86        \[M−H\]       835.3742               835.3752                 C~42~H~60~O~17~   823→661, 351                  24-hydroxyl-licorice-saponin E2                                                G               \[[@B27-molecules-20-01594]\]
  102        14.00        \[M−H\]       837.3891               837.3909                 C~42~H~62~O~17~   837→819, 775, 661, 351        licorice saponin G2                                                            G               \[[@B27-molecules-20-01594]\]
  103        14.00        \[M−H\]       967.4523               967.4539                 C~48~H~72~O~20~   967→805,497, 407, 321         rhaoglycyrrhizin                                                               G               \[[@B27-molecules-20-01594]\]
  104        14.01        \[M−H\]       819.3787               819.3803                 C~42~H~60~O~16~   819→777, 643, 351             licorice saponin E2                                                            G               \[[@B27-molecules-20-01594]\]
  105        14.06        \[M−H\]       863.4049               863.4065                 C~44~H~64~O~17~   863→819, 729, 687, 351, 289   22-acetoxyl-glycyrrhaldehyde                                                   G               \[[@B27-molecules-20-01594]\]
  106        14.13        \[M−H\]       255.0660               255.0657                 C~15~H~12~O~4~    255→135                       isoliquiritigenin                                                              G               \[[@B27-molecules-20-01594]\]
  107        14.14        \[M−H\]       821.3945               821.3945                 C~42~H~62~O~16~   821→803, 759, 645, 351        glycyrrhizin                                                                   G               \[[@B27-molecules-20-01594]\]
  108        14.33        \[M−H\]       821.3945               821.3960                 C~42~H~62~O~16~   821→803, 759, 645, 351        18α-glycyrrhizin                                                               G               \[[@B27-molecules-20-01594]\]

Note: ^a^: A, *Arnebiae* radix; C, *Curcumae* rhizome; G, *Glycyrrhizae* radix et rhizome; M, *Mume* fructus; P, *Paeoniae* radix rubra; Sa, *Sarcandrae Herba*; Sm, *Smilacis glabrae* rhizome.

2.3. Method Validation of the Quantitative Analysis
---------------------------------------------------

The calibration curves, linear ranges, LOQ, and repeatability of the 14 analytes were established using the developed UHPLC-MS method ([Table 2](#molecules-20-01594-t002){ref-type="table"}). Reasonable correlation coefficient values (*r*^2^ \> 0.9981) indicated good correlations between the investigated concentrations of the standards and their peak areas within the ranges tested. The ranges of LOQ for all the analytes were from 0.013 to 0.065 μg/mL.
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###### 

Calibration curves, linear range, LOQ and repeatability for fourteen compounds analyzed with the UHPLC-MS system.

  Analyte                              Linear Range (μg/mL)   Calibration Curve (*n* = 7)     *r*^2^   LOQ (μg/mL)   Repeatability RSD (%)
  ------------------------------------ ---------------------- ------------------------------- -------- ------------- -----------------------
  3-*O*-Caffeoylquinic acid (**16**)   0.16--6.37             *y* = 301,311 *x*− 46,304       0.9984   0.064         2.3
  5-*O*-Caffeoylquinic acid (**22**)   0.23--9.24             *y* = 341,667 *x*− 39,368       0.9982   0.046         3.2
  4-*O*-Caffeoylquinic acid (**24**)   0.41--16.34            *y* = 267,929 *x*− 80,795       0.9990   0.065         3.8
  5-*O*-Caffeoylskimic acid (**39**)   0.57--22.92            *y* = 396,547 *x* + 152,855     0.9985   0.057         3.5
  Paeoniflorin (**40**)                2.54--101.62           *y* = 207,558 *x* + 1,315,316   0.9988   0.040         1.7
  Liquiritin (**51**)                  0.46--18.24            *y* = 616,184 *x*+ 109,090      0.9987   0.036         1.8
  Neoastilbin (**56**)                 0.47--18.84            *y* = 572,723 *x* + 139,006     0.9983   0.016         1.7
  Astilbin (**60**)                    0.55--22.16            *y* = 500,903 *x* + 165,817     0.9990   0.055         1.5
  Neoisoastilbin (**64**)              0.39--15.77            *y* = 339,480 *x* + 93,661      0.9986   0.067         2.0
  Isoastilbin (**67**)                 0.32--12.84            *y* = 531,497 *x*− 76,292       0.9984   0.018         1.5
  Engeletin (**79**)                   0.31--12.50            *y* = 743,986 *x*− 120,215      0.9983   0.013         2.1
  Isoengeletin (**82**)                0.67--26.66            *y* = 355,937 *x*+ 110,394      0.9987   0.027         3.8
  Liquiritigenin (**87**)              0.07--2.96             *y* = 426,840 *x*− 24,980       0.9981   0.030         2.0
  glycyrrhizic acid (**107**)          0.99--39.56            *y* = 422,502 *x*+ 468,934      0.9986   0.040         1.6
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###### 

Intra-day and inter-day precisions and recoveries for fourteen compounds analyzed with the UHPLC-MS system.

  Analyte                              Intra-Day (RSD, %) (*n* = 6)   Inter-Day (RSD, %) (*n* = 3)   Recoveries (*n* = 6)                           
  ------------------------------------ ------------------------------ ------------------------------ ---------------------- ------- ------- ------- -----
  3-*O*-Caffeoylquinic acid (**16**)   2.9                            2.8                            1.71                   1.75    3.23    92.6    4.8
  5-*O*-Caffeoylquinic acid (**22**)   1.3                            4.4                            1.38                   1.27    2.87    108.4   3.8
  4-*O*-Caffeoylquinic acid (**24**)   1.3                            3.4                            2.07                   2.25    4.51    104.1   3.4
  5-*O*-Caffeoylskimic acid (**39**)   0.6                            3.7                            2.99                   3.15    5.54    90.2    1.4
  Paeoniflorin (**40**)                3.2                            2.7                            27.34                  27.95   57.69   104.5   3.8
  Liquiritin (**51**)                  2.9                            2.5                            4.95                   5.02    10.05   101.3   2.5
  Neoastilbin (**56**)                 1.9                            3.1                            5.25                   5.18    11.38   109.5   2.3
  Astilbin (**60**)                    3.4                            3.0                            6.02                   6.10    11.86   97.8    3.7
  Neoisoastilbin (**64**)              3.0                            3.2                            4.24                   4.34    8.21    95.6    3.9
  Isoastilbin (**67**)                 3.2                            3.1                            3.60                   3.53    7.49    105.1   3.2
  Engeletin (**79**)                   2.5                            2.8                            3.31                   3.44    6.99    104.1   4.1
  Isoengeletin (**82**)                3.8                            2.3                            2.51                   2.62    4.83    94.4    3.0
  Liquiritigenin (**87**)              2.3                            2.6                            0.82                   0.81    1.52    93.2    2.4
  glycyrrhizic acid (**107**)          0.8                            1.5                            10.75                  10.88   22.83   106.0   2.1

The repeatability presented as RSD (*n* = 5) was between 1.5% and 3.8% for the 14 compounds. The overall intra- and inter-day variations (RSD) of the 14 analytes were in the range from 0.6% to 3.8%, and 1.5 to 4.4% ([Table 3](#molecules-20-01594-t003){ref-type="table"}), respectively. The developed method had good accuracy with the recoveries were between 86.3% and 109.5% ([Table 3](#molecules-20-01594-t003){ref-type="table"}). Therefore, the results demonstrated that the UHPLC-ESI-MS method was sensitive, precise, and accurate enough for quantitative evaluation of multi-compounds in PSORI-CM01 preparations.

2.4. Quantitative Determination of PSORI-CM01 Preparations
----------------------------------------------------------

A total of eight different batches of PSORI-CM01 preparations were tested using the developed LC-ESI-MS method. The contents (*n* = 3) of 14 investigated compounds are summarized in [Table 4](#molecules-20-01594-t004){ref-type="table"}. It was recognized that 3-*O*-caffeoylquinic acid (**16**), 5-*O*-caffeoylquinic acid (**22**), 4-*O*-caffeoylquinic acid (**24**), 5-*O*-caffeoylskimic acid (**39**), paeoniflorin (**40**), liquiritin (**51**), neoastilbin (**56**), astilbin (**60**), neoisoastilbin (**64**), isoastilbin (**67**), and glycyrrhizic acid (**107**) were the dominant compounds in all examined samples. However, the contents of each compound or the total content of certain type of constituents varied in different PSORI-CM01 preparation.
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###### 

The contents of the 14 compounds in different batches of PSORI-CM01 prepations (*n* = 3).

  Analyte ^a^                          KLJ-1     KLJ-2     PJ-3      PJ-4      PJ-5      TJ-6      TJ-7     TJ-8
  ------------------------------------ --------- --------- --------- --------- --------- --------- -------- ---------
  3-*O*-Caffeoylquinic acid (**16**)   520.94    531.48    391.56    132.01    429.07    122.89    30.68    121.18
  5-*O*-Caffeoylquinic acid (**22**)   514.55    503.94    391.56    146.51    488.10    123.45    27.30    183.64
  4-*O*-Caffeoylquinic acid (**24**)   601.74    545.00    558.82    211.85    683.57    129.75    40.53    160.64
  5-*O*-Caffeoylskimic acid (**39**)   540.55    520.10    789.39    324.27    397.06    333.60    153.44   429.46
  Paeoniflorin (**40**)                5855.02   6030.52   7218.12   5177.23   5368.14   2326.21   445.51   3511.46
  Liquiritin (**51**)                  1654.18   1650.73   892.15    360.64    1115.65   145.56    71.55    248.20
  Neoastilbin (**56**)                 2545.86   2767.29   2442.62   423.15    1680.52   369.88    124.41   588.89
  Astilbin (**60**)                    3819.23   4061.92   3743.95   844.53    2575.83   661.96    174.14   879.05
  Neoisoastilbin (**64**)              2459.06   2359.70   1872.94   736.75    2211.36   605.51    154.36   802.79
  Isoastilbin (**67**)                 879.60    916.61    650.53    260.87    902.06    244.03    74.96    418.97
  Engeletin (**79**)                   678.32    740.00    503.10    196.27    621.69    165.13    84.25    274.81
  Isoengeletin (**82**)                543.19    1089.55   348.12    132.29    331.67    119.27    16.30    116.39
  Liquiritigenin (**87**)              224.07    246.07    477.28    62.14     202.73    75.50     24.55    130.18
  glycyrrhizic acid (**107**)          2225.13   2359.89   2610.50   933.51    2770.51   306.01    68.44    257.72

Notes: ^a^ The content unit of granule (KLJ-1, KLJ-2) and pills (PJ-3, PJ-4, PJ-5) was expressed as μg/g; The content unit of decoction was ug/mL.

In order to evaluate the variations in detail, hierarchical cluster analysis was performed based on the contents of 14 analytes of the eight investigated batches. Between-groups linkages method was applied, and Squared Euclidean distance was selected as measurement. [Figure 2](#molecules-20-01594-f002){ref-type="fig"} shows the results on the investigated batches of PSORI-CM01 preparations, which were divided into two main clusters. The results suggested that the contents of 14 analytes were relatively more stable and higher in granule preparations (the batches of K1 and K2) but varied in tablet and decoction preparations. This may be related to the origin of raw medicinal plants origin and extraction technology and so on. As mentioned above, 3-*O*-caffeoylquinic acid (**16**), paeoniflorin (**40**), liquiritin (**51**), astilbin (**60**), engeletin (**79**), liquiritigenin (**87**) and glycyrrhizic acid (**107**) may be the main active components of PSORI-CM01, The content of the six ingredients should be stressed on in establishing quality control methods for PSORI-CM01 preparations.

![Dendrogram of hierarchical cluster analysis for the eight investigated batches of PSORI-CM01 preparations.](molecules-20-01594-g002){#molecules-20-01594-f002}

3. Experimental Section
=======================

3.1. Chemicals and Materials
----------------------------

Methanol and acetonitrile (HPLC grade) were purchased from Fisher Scientific (Fair Lawn, NJ, USA); Formic acid (HPLC grade) was purchased from the Sigma-Aldrich (Seelze, Germany); Ultra-pure water was prepared using a Millipore Milli-Q purification system (Bedford, MA, USA).

5-*O*-caffeoylskimic acid (**39**), paeoniflorin (**40**), neoastilbin (**56**), astilbin (**60**), neoisoastilbin (**64**), isoastilbin (**67**), engeletin (**79**) and isoengeletin (**82**) were isolated in our lab and identified by the authors. 3-*O*-caffeoylquinic acid (**16**), 5-*O*-caffeoylquinic acid (**22**), 4-*O*-caffeoylquinic acid (**24**), liquiritin (**51**), liquiritigenin (**87**), and glycyrrhizic acid (**107**) were purchase from the National Institutes for Food and Drug Control (Beijing, China). All of the purities were above 98% by HPLC analysis. Eight batches of PSORI-CM01 preparations were supplied by Guangdong Provincial Hospital of Chinese Medicine, and voucher samples were deposited in the laboratory of Materia Medica Preparation, Guangdong Province Academy of Chinese Medicine Science.

3.2. Standard Solutions and Sample Preparation
----------------------------------------------

Stock solutions of the 14 reference substances were prepared in concentrations ranging from 0.420 to 5.083 mg/mL in 60% methanol and stored at 4 °C until use. A standard working solution of the mixtures was obtained by diluting stock solutions to desired concentrations. Aliquots of this solution were further diluted with initial mobile phase to a series of concentrations for quantification.

PSORI-CM01 preparations (granules and tablets) were pulverized into a fine powder. The powder (0.5 g) was accurately weighed, immersed in 60% MeOH (v/v, 10 mL) for 1 h at room temperature, then extracted in an ultrasonic water bath for 30 min. After recording the weight, the extract was filtered through filter paper. Aliquots of 500 μL of filtrate was transferred into a 5 mL volumetric flask which was made up to its volume with initial mobile phase. PSORI-CM01 decoction was diluted 10 times in 60% MeOH (v/v) for quantitative analysis. All of the samples were filtered through a 0.22 μm syringe filter before use, and 10 μL was injected into the LC instrument for LC-MS analysis.

3.3. UHPLC-ESI-MS/MS System
---------------------------

Chromatographic separation was performed on an Accela™ ultra high pressure liquid chromatography (UHPLC) system (Thermo Fisher Scientific, San Jose, CA, USA) comprising a UHPLC pump, a PDA detector, scanning from 200 to 400 nm, and an autosampler settled to 30 °C. The LC conditions were as follows: column: Thermo Scientific Syncronis C18 (50 mm × 2.1 mm, 1.7 μm); mobile phase: acetonitrile (A) and water containing 0.1% (v/v) formic acid (B); gradient: 0 min, 5:95; 10 min, 27:83; 15 min, 50:50; 18--20 min, 100:0 (A:B, v/v); flow rate: 0.4 mL/min; injection volume: 10 μL.

The above UHPLC system was connected with a LTQ/Orbitrap mass spectrometry system (Thermo-Fisher Scientific, Bremen, Germany) via an ESI interface. High purity nitrogen (N~2~) was used as the sheath gas and helium (He) as the auxiliary gas with a flow rate of 40 and 10 arbitrary units, respectively.

3.4. Qualitative Characteristic of Chemical Constituents
--------------------------------------------------------

Identification of chemical constituents in PSORI-CM01 preparations was performed by LC-ESI-MS^n^ analysis. The ESI-MS spectra of samples and reference compounds were acquired in negative ionization mode. The parameters were as follows: capillary temperature at 320 °C, capillary voltage at −28 V, ion spray voltage at −4.0 kV, and tube lens voltage at −90 V. For full scan MS analysis, the spectra were recorded in the range of *m/z* 100--1500 with a resolution of 30,000. Data-dependant acquisition was applied and the most intense ions detected in each MS scan were selected for MS^n^ data records with a resolution of 15,000. The activation time was 30 ms and the collision energy was adjusted to 35%. Data were processed by Xcalibur software (Thermo-Fisher Scientific, Bremen, Germany). An external calibration for mass accuracy was carried out the day before the analysis according to the manufacturer's guidelines.

3.5. Validation of the Quantitative Analysis
--------------------------------------------

The stock solution containing 14 reference compounds was prepared and diluted to seven-point calibration levels for the construction of calibration curves. Each concentration of the mixed standard solution was injected in triplicate. Calibration curves were established by plotting the peak area *versus* concentration of each analyte. Intra- and inter-day variations were utilized to assess the precision of the method. The intra-day variation was determined by analyzing six replicates within 1 day and the inter-day variation was examined in three consecutive days. Recovery was used to evaluate the accuracy of the method. Recovery test was carried out to investigate accuracy of this method by adding certain amounts of the 14 standard solutions to 0.25 g powder of sample in sextuplicate. Samples were processed as described in [Section 2.2](#sec2dot2-molecules-20-01594){ref-type="sec"}. To confirm the repeatability, five replicates of the same sample were extracted and analyzed. Variations were expressed by relative standard deviation (RSD) in all three tests above.

4. Conclusions
==============

An efficient and sensitive method employing ultra-high liquid chromatography coupled with linear trap quadrupole and high resolution mass analyzer-orbitrap (UHPLC-LTQ/Orbitrap) was developed for the qualitative and quantitative analysis of chemical constituents of PSORI-CM01 preparations. One hundred and eight compounds, including organic acids, phenolic acids, flavonoids, and terpenoids, were characterized on the basis of retention behaviors, abundant MS and MS^n^ data, or by comparing with reference substances and literatures. All compounds identified were found to be existed in individual traditional Chinese medicines of PSORI-CM01 preparation. However, the characteristic constituents from *Rhizoma Curcumae* were not detected. Further investigation focused on those lipophilic constituents in PSORI-CM01 preparation is required.

An optimized LC-ESI-MS method was then established for assay of the 14 marker compounds in PSORI-CM01 preparations. The validation of the method, represent a good accuracy, sensitivity and repeatability. The quantification results indicated an obvious difference of marker compounds contents among various samples. This is the first report on the comprehensive determination of chemical constituents in PSORI-CM01 preparations by LC-ESI-MS^n^. The results would provide the chemical support for the further pharmacokinetic studies and for the improvement of quality control of PSORI-CM01 preparations. The study also suggested that LC-LTQ/Orbitrap-MS would be a powerful and reliable analytical tool for the characterization of chemical profile in complex chemical system, such as TCM preparations.

This research was financially supported by Guangdong Natural Science Fund (S2013030011515), Guangdong Financial Industry Technology Research Development Fund \[2011(285)05\], Guangdong Science and Technology Department-Guangdong Province Academy of Chinese Medicine Science Joint Special Fund (2011B032200009) and Guangdong Provincial Hospital of Chinese Medicine Special Fund (YK2013B1N11).

*Sample Availability*: Samples of the compounds **16**, **22**, **24**, **39**, **40**, **51**, **56**, **60**, **64**, **67**, **79**, **82**, **87** and **107** are available from the authors.

C.-J. Lu designed the experiments and provided critical advice on operation of the analytical equipment. S.-D. Chen was responsible for performing most of the experiment and analysis, and preparing the draft of the manuscript. R.-Z. Zhao helped revising the manuscript.

The authors declare no conflict of interest.
